T-20 (Enfuvirtide, Fuzeon) Research
- Continuous Infusion of T-20 in Multidrug Resistant Patient With Intolerance of Subcutaneous Injections (May/June 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- People Who Use Fuzeon May Be at 34 Percent Higher Risk for Pneumonia (May 2, 2011)
From Project Inform
On TheBodyPRO.com
- Needle-Free Mode of T-20 Dosing Looks Highly Satisfactory for Patients (August 28, 2006)
From aidsmap.com
- HIV JournalView: Disappointing Results With Once-Daily Enfuvirtide (February/March 2006)
- HIV JournalView: Enfuvirtide: Is Needleless Dosing Possible? (February/March 2006)
- Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006 (July 22, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Warns Roche About Misleading Comments Made by Salesperson Regarding Fuzeon (July 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Roche, Trimeris Seek FDA Approval to Use Needle-Free Injection Device to Administer Antiretroviral Fuzeon (July 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Severe Enfuvirtide Injection Site Reactions Tied to Lack of Subcutaneous Fat (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions (October 22, 2004)
From U.S. Food and Drug Administration
On TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|